Breast cancer is the most common malignant disease and among the most frequent causes of cancer mortality in females worldwide. Metastatic breast cancer (MBC) is conventionally considered to be incurable. 
Introduction
Metastatic breast cancer (MBC) is conventionally considered to be incurable, with median survival estimates to be in the range of 3 years [1] . Overexpression of human epidermal growth factor receptor type 2 (HER2) occurs in 20-25% of invasive breast cancers, which is associated with a poor prognosis, shortened disease-free interval and high mortality rate [2, 3] . Trastuzumab is a monoclonal antibody targeting the external domain of the c-erb-2 receptor. In first-line treatment of HER2-positive MBC, randomized trials have demonstrated that trastuzumab when combined with paclitaxel or docetaxel significantly improves median time to progression objective response and overall survival [3, 4] . The purpose of this study is to evaluate the efficacy and safety of Trastuzumab plus chemotherapy in metastatic breast cancer HER2 positive in clinical practice in a sample Moroccan population.
Methods
This is a prospective observational institutional study conducted at 
Results
A total of 20 patients were enrolled. The median age of patients was 43.5 years. Most of patients had received adjuvant chemotherapy (80%), and all were naive of Trastuzumab. Most of our sample was hormone receptor positive (85%). The number of metastatic site was variable, 50% of patients had one metastatic site and 20% more than 2 sites; the lung was the first metastatic site involved in 60%, followed by bone (50%), liver, nodes, skin and brain. The patient's characteristics are resumed in Table 1 .
However, it should be stressed that percentages of metastatic sites do not add up to 100% because of overlapping.
Treatment delivered Chemotherapeutic regimens used were different. Nine patients (45%) received Docetaxel (100 mg/m2) every 3 weeks, while 8 other patients (40%) were treated with Vinorelbine (25 mg/m2 at day 1 and 8) every 3 weeks, and 3 patients (15%) with Capecitabine (1000 mg/m2 from day 1 to 14) every three weeks. Trastuzumab was administered every 3 weeks with 8 mg/kg in the first cycle and at subsequent cycles with 6 mg/kg. The median number of chemotherapy cycles received was 9 cycles, and the median of trastuzumab cycles was 15 as shown in Table 2 . However for 2 patients (10%), the disease was progressing. (Table   Page number not for citation purposes   3 3) The median progression free survival was estimated at 12.8 months as shown in Kaplan Meir curve (Figure 1 ) and the median overall survival was estimated at 24.5 months. 
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